RU2019133327A - Способ лечения побочного эффекта терапии Т-клетками с химерными антигенными рецепторами (CAR) - Google Patents

Способ лечения побочного эффекта терапии Т-клетками с химерными антигенными рецепторами (CAR) Download PDF

Info

Publication number
RU2019133327A
RU2019133327A RU2019133327A RU2019133327A RU2019133327A RU 2019133327 A RU2019133327 A RU 2019133327A RU 2019133327 A RU2019133327 A RU 2019133327A RU 2019133327 A RU2019133327 A RU 2019133327A RU 2019133327 A RU2019133327 A RU 2019133327A
Authority
RU
Russia
Prior art keywords
car
msc
mir
subject
cell
Prior art date
Application number
RU2019133327A
Other languages
English (en)
Inventor
Килиан КЕЛЛИ
Игорь СЛУКВИН
Original Assignee
Сината Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901273A external-priority patent/AU2017901273A0/en
Application filed by Сината Терапьютикс Лимитед filed Critical Сината Терапьютикс Лимитед
Publication of RU2019133327A publication Critical patent/RU2019133327A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Claims (18)

1. Способ лечения побочного эффекта CAR Т-клеточной (Т-клетками с химерными антигенными рецепторами) терапии, включающий введение мезенхимальных стволовых клеток (MSC) субъекту, который получал или получает CAR Т-клеточную терапию.
2. Применение мезенхимальных стволовых клеток (MSC) в изготовлении лекарственного средства для лечения побочного эффекта CAR Т-клеточной терапии у субъекта, который получал или получает CAR Т-клеточную терапию.
3. Способ по п. 1 или применение по п. 2, где MSC имеет фенотип CD73+CD105+CD90+CD146+CD44+CD10+CD31-CD45-.
4. Способ или применение по любому из пп. 1-3, где субъекту вводят от примерно 1×106 MSC/кг до примерно 1×107 MSC/кг.
5. Способ или применение по любому из пп. 1-4, где MSC экспрессирует miR-145-5р, miR-181b-5p и miR-214-3р, но не miR-127-3р и miR-299-5p.
6. Способ или применение по любому из пп. 1-5, где лечение включает введение субъекту от примерно 1×108 до примерно 5×108 MSC.
7. Способ или применение по любому из пп 1-6, где лечение включает введение MSC до, во время или после получения субъектом CAR Т-клеточной терапии.
8. Способ или применение по любому из пп. 1-7, где лечение включает введение MSC после получения субъектом CAR Т-клеточной терапии.
9. Способ или применение по п. 8, где лечение включает введение MSC в пределах от 24 часов до 72 часов после получения субъектом CAR Т-клеточной терапии.
10. Способ или применение по любому из пп. 1-9, где побочный эффект или симптом представляет собой: синдром высвобождения цитокинов (CRS), возможно высвобождение интерлейкина-6 (IL-6), интерферона-γ (IFN-γ), фактора некроза опухоли (TNF), IL-2, IL-2-рецептора α, IL-8, IL-10 или гранулоцитарно-макрофагального колониестимулирующего фактора (GMCSF); синдром активации макрофагов (MAS); целенаправленный, не связанный с раком эффект, возможно В-клеточную аплазию; синдром лизиса опухоли (TLS); нейротоксичность, возможно отек головного мозга; или анафилаксию.
11. Способ или применение по любому из пп. 1-10, где CAR Т-клеточная терапия предназначена для лечения: диффузной крупноклеточной В-клеточной лимфомы (DLBCL); неходжкинской лимфомы (NHL); первичной медиастинальной В-клеточной лимфомы (PMBCL); хронического лимфоцитарного лейкоза (CLL); трансформированной фолликулярной лимфомы (TFL); множественной миеломы (ММ); мантийноклеточной лимфомы (MCL); острого миелолейкоза (AML); или острого лимфобластного лейкоза (ALL).
12. Способ или применение по любому из пп. 1-11, где CAR представляет собой анти-CD19 CAR.
13. Способ или применение по любому из пп. 1-12, где субъект представляет собой млекопитающее, возможно человека.
14. Терапевтическая композиция для лечения, ослабления или уменьшения побочного эффекта CAR Т-клеточной терапии у субъекта-млекопитающего, которая содержит мезенхимальную стволовую клетку (MSC), полученную способом, включающим:
(а) культивирование первичной мезодермальной клетки в среде для формирования мезенхимальных колоний (M-CFM), содержащей LiCl и FGF2 (фактор роста фибробластов 2), но не содержащей PDGF (тромбоцитарный фактор роста), в условиях с нормальным содержанием кислорода в течение достаточного времени для формирования мезенхимальной колонии; и
(б) культивирование мезенхимальной колонии со стадии (а) в прикрепленном состоянии с получением MSC,
где MSC со стадии (б) экспрессирует miR-145-5p, miR-181b-5p и miR-214-3р, но не miR-127-3р и miR-299-5p, и/или имеет фенотип CD73+CD105+CD90+CD146+CD44+CD10+CD31-CD45-.
15. Контейнер, содержащий терапевтическую композицию по п. 14.
RU2019133327A 2017-04-07 2018-04-09 Способ лечения побочного эффекта терапии Т-клетками с химерными антигенными рецепторами (CAR) RU2019133327A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017901273A AU2017901273A0 (en) 2017-04-07 Method
AU2017901273 2017-04-07
PCT/AU2018/050321 WO2018184074A1 (en) 2017-04-07 2018-04-09 Method for treating a side effect of chimeric antigen receptor (car) t cell therapy

Publications (1)

Publication Number Publication Date
RU2019133327A true RU2019133327A (ru) 2021-05-07

Family

ID=63711950

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019133327A RU2019133327A (ru) 2017-04-07 2018-04-09 Способ лечения побочного эффекта терапии Т-клетками с химерными антигенными рецепторами (CAR)

Country Status (11)

Country Link
EP (1) EP3606540A1 (ru)
JP (1) JP2020516605A (ru)
KR (1) KR20190133254A (ru)
CN (1) CN110678191A (ru)
AU (1) AU2018248071A1 (ru)
BR (1) BR112019020848A2 (ru)
CA (1) CA3059249A1 (ru)
MX (1) MX2019011847A (ru)
RU (1) RU2019133327A (ru)
SG (1) SG11201909201SA (ru)
WO (1) WO2018184074A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141731A1 (en) * 2013-03-13 2014-10-09 Wisconsin Alumni Research Foundation Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
AU2015306231B2 (en) * 2014-08-18 2019-11-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
US20180136209A1 (en) * 2015-06-03 2018-05-17 Aelan Cell Technologies, Inc. Companion methods and kits for il-2-based therapies and mesenchymal stem cell-based therapies
SG11201807114TA (en) * 2016-03-16 2018-09-27 Cynata Therapeutics Ltd Colony forming medium and use thereof
EP3730607A1 (en) * 2016-04-01 2020-10-28 Apceth GmbH & Co. KG Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy

Also Published As

Publication number Publication date
CN110678191A (zh) 2020-01-10
BR112019020848A2 (pt) 2020-06-02
SG11201909201SA (en) 2019-11-28
EP3606540A1 (en) 2020-02-12
AU2018248071A1 (en) 2019-10-17
MX2019011847A (es) 2019-11-21
WO2018184074A1 (en) 2018-10-11
JP2020516605A (ja) 2020-06-11
KR20190133254A (ko) 2019-12-02
CA3059249A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
Shan et al. The pathophysiology of thyroid eye disease
BR112022026208A2 (pt) Anticorpos de ccr8 para aplicações terapêuticas
Cheng et al. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours
JP2021503923A5 (ru)
WO2019094642A8 (en) T cell manufacturing compositions and methods
MX2019001185A (es) Polipeptidos inmunomoduladores y composiciones y metodos relacionados.
Alizadeh et al. The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer
RU2019143743A (ru) Способ лечения побочного эффекта иммунотерапии
JP2019504105A5 (ru)
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
PH12020551251A1 (en) Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP2019510035A (ja) 細胞傷害性細胞及び幹細胞の治療効果を強化する新規なｒｎａ構築物及びその使用方法
EP2547360A4 (en) SYSTEM AND METHOD FOR THE PRODUCTION AND STORAGE OF ACTIVATED TIRES OF DENDRITIC CELLS
HRP20220419T1 (hr) Terapija matičnim stanicama kod patologija endometrija
MX2022010340A (es) Celulas t con car de bcma con actividades mejoradas.
RU2019133327A (ru) Способ лечения побочного эффекта терапии Т-клетками с химерными антигенными рецепторами (CAR)
MX2021005485A (es) Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
MX2021004231A (es) Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos.
MX2021012961A (es) Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
JP2016510594A5 (ru)
JP2024016037A5 (ru)
EP2534242A1 (en) Improved composition for inhibiting tumor cell proliferation
JP2018522880A5 (ru)
CN113194715A (zh) 用于治疗癌症的材料和方法
JP2022163062A (ja) Ｃｃｒ２＋造血幹細胞は養子細胞療法におけるｔ細胞活性化を媒介する

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20210412